title: Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.
abstract: We analyzed outcome of a population-based cohort of 74 children with second and third acute lymphoblastic leukemia (ALL) relapse and aimed to identify prognostic factors. Duration of previous remission and site of relapse appeared of prognostic relevance as patients with a second remission duration >1.5 years and isolated extramedullary relapse did better. Neither patient with a second bone marrow relapse who underwent previous allogeneic transplantation nor patients with T-cell ALL survived. Overall, 7 of 74 (9%) patients are in long-term remission. Stem cell transplantation seemed to be the only curative option for systemic relapse of B-cell precursor ALL as all 4 surviving patients with a second/third relapse involving the bone marrow received a transplant. Conclusively, patients with a second ALL relapse are ideal candidates for phase I/II trials exploring new innovative drugs.
authors: Pediatric Hematology and Oncology, Department of Pediatrics, St Anna Children's Hospital, Medical University of Vienna, Austria.
authors: Bettina
authors: B
authors: Reismüller
authors: Christina
authors: C
authors: Peters
authors: Michael N
authors: MN
authors: Dworzak
authors: Ulrike
authors: U
authors: Pötschger
authors: Christian
authors: C
authors: Urban
authors: Bernhard
authors: B
authors: Meister
authors: Klaus
authors: K
authors: Schmitt
authors: Karin
authors: K
authors: Dieckmann
authors: Helmut
authors: H
authors: Gadner
authors: Andishe
authors: A
authors: Attarbaschi
authors: Georg
authors: G
authors: Mann
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001315:Australia; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality* / Q000628:therapy*; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents